"Selpercatinib"

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 19 February 2025 www.nice.org.uk/guidance/ta1042 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lungcancer (TA1042)© NICE 2025. All rights reserved. Subject to Notice

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over Technology appraisal guidance Published: 12 February 2025 www.nice.org.uk/guidance/ta1038 © NICE 2025. All rights reserved to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for advanced thyroid cancer with RET alterations after treatment

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over Technology appraisal guidance Published: 12 February 2025 www.nice.org.uk/guidance/ta1039 © NICE 2025. All rights reserved. Subject unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for advanced thyroid cancer with RET alterations untreated

Selpercatinib (thyroid cancer) - Benefit assessment according to ' 35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Selpercatinib (RET-Fusions-positives Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However , solely the German original text is absolutely authoritative and legally binding. Selpercatinib (RET fusion-positive thyroid cancer) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-62 Version: 1.0 Status: 8 Aug 2024 DOI: 10.60584/A24-62_en Extract of dossier assessment A24-62 Version 1.0 Selpercatinib ( RET fusion-positive thyroid cancer) 8 Aug 2024 Institute for Quality and Efficiency

Selpercatinib (solid tumours) - Benefit assessment according to ' 35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Selpercatinib (RET-Fusions-positive solide Tumoren) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Selpercatinib (RET fusion-positive solid tumours) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-63 Version: 1.0 Status: 31 Jul 2024 DOI: 10.60584/A24-63_en Extract of dossier assessment A24-63 Version 1.0 Selpercatinib ( RET fusion-positive solid tumours) 31 Jul 2024 Institute for Quality and Efficiency in Health

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 26 July 2023 www.nice.org.uk/guidance/ta911 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer(TA911)© NICE 2023. All rights reserved. Subject

Selpercatinib (thyroid cancer) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Selpercatinib (RET-mutiertes medulläres Schilddrüsenkarzinom, Erstlinie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 22 December 2022). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-106 Selpercatinib (RET-mutant medullary thyroid cancer, first line) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-106 Version 1.0 Selpercatinib (RET-mutant medullary thyroid cancer

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 12 January 2022 www.nice.org.uk/guidance/ta760 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of24Contents Contents 1 Recommendations

Selpercatinib (Retsevmo) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. ENGLISH | DEUTSCH ATOM RSS 1.0 RSS 2.0SIMPLE SEARCHADVANCED SEARCHHELPSERVICESLOGINBrowseTypeSubjectAuthor / EditorInstitutionYear AIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancerRothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Fact Sheet Nr. 163. PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader135kBItem Type: Horizon

Selpercatinib (Retsevmo) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * Year AIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours Rothschedl, E. and Grössmann, N.(2024):Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive

Selpercatinib for treating advanced thyroid cancer with RET alterations Selpercatinib for treating advanced thyroid cancer with RET alterations Technology appraisal guidance Published: 3 November 2021 www.nice.org.uk/guidance/ta742 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility Your responsibility impact of implementing NICE recommendations wherever possible. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)© NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of22Contents Contents 1 Recommendations

Selpercatinib (advanced NSCLC with RET fusion) ' Benefit assessment according to ' 35a SGB V 1 Translation of Sections I 1 to I 5 of the dossier assessment Selpercatinib (RET-Fusions-positives NSCLC, Erstlinie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 September 2022). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-65 Selpercatinib (RET fusion-positive NSCLC, first line) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-65 Version 1.0 Selpercatinib (RET fusion-positive NSCLC, first line) 28 September 2022

Selpercatinib (Retsevmo) - rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) 1 Published 13 November 2023 1 SMC2573 selpercatinib hard capsules (Retsevmo®) Eli Lilly and Company Limited 06 October 2023 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan equivalent medicine process selpercatinib (Retsevmo®) is accepted for restricted use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication Under Review: monotherapy for the treatment of adults

Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Selpercatinib (RET-Fusions-positives Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 June 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-29 Selpercatinib (RET fusion-positive thyroid cancer) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-29 Version 1.0 Selpercatinib (RET fusion-positive thyroid cancer

Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Selbercatinib (RET-Fusions-positives NSCLC) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 June 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-27 Selpercatinib (RET fusion-positive NSCLC) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-27 Version 1.0 Selpercatinib (RET fusion-positive NSCLC) 11 June 2021 Institute for Quality and Efficiency

Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Selpercatinib (RET-mutiertes medulläres Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 June 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-28 Selpercatinib (RET-mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-28 Version 1.0 Selpercatinib (RET-mutant medullary thyroid cancer

Selpercatinib Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health

Selpercatinib (Retevmo) - cancers that harbour genetic alterations in the rearranged during transfection (RET) gene Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health

Selpercatinib (Retsevmo) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC) Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC) Rothschedl, E. and Wolf, S.(2022):Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 95.Preview PDF

Selpercatinib (Retsevmo) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) Rothschedl, E. and Wolf, S.(2022):Selpercatinib (Retsevmo®) as monotherapy for the treatment